Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Leases (2019 - 2025)

Historic Current Leases for Autolus Therapeutics (AUTL) over the last 7 years, with Q3 2025 value amounting to $4.8 million.

  • Autolus Therapeutics' Current Leases rose 3531.39% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 3531.39%. This contributed to the annual value of $3.0 million for FY2024, which is 4066.89% down from last year.
  • As of Q3 2025, Autolus Therapeutics' Current Leases stood at $4.8 million, which was up 3531.39% from $3.3 million recorded in Q2 2025.
  • Autolus Therapeutics' Current Leases' 5-year high stood at $6.2 million during Q2 2023, with a 5-year trough of $3.0 million in Q1 2025.
  • In the last 5 years, Autolus Therapeutics' Current Leases had a median value of $4.3 million in 2021 and averaged $4.4 million.
  • Its Current Leases has fluctuated over the past 5 years, first skyrocketed by 5597.0% in 2023, then crashed by 4066.89% in 2024.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Current Leases stood at $4.5 million in 2021, then grew by 13.14% to $5.0 million in 2022, then increased by 0.3% to $5.1 million in 2023, then plummeted by 40.67% to $3.0 million in 2024, then skyrocketed by 61.04% to $4.8 million in 2025.
  • Its Current Leases stands at $4.8 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.0 million for Q1 2025.